Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA E-Labeling Rule Designed To Aid Drug Comparisons By Physicians, Patients

Executive Summary

An FDA electronic labeling archive will help physicians and consumers make head-to-head comparisons between drugs, Commissioner McClellan said Dec. 9

You may also be interested in...



FDA Proposes E-Labeling Shift To “Structured Product Labeling” Format

FDA is moving toward processing electronic submissions in a "structured product labeling" format rather than the portable document format (PDF), a draft guidance on e-labeling says

FDA Proposes E-Labeling Shift To “Structured Product Labeling” Format

FDA is moving toward processing electronic submissions in a "structured product labeling" format rather than the portable document format (PDF), a draft guidance on e-labeling says

Electronic INDs For Cancer Trials Planned Under FDA/NCI Collaboration

Creating a mechanism for electronic IND applications will be the first project undertaken by a collaboration between FDA and the National Cancer Institute

UsernamePublicRestriction

Register

PS042977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel